Warning Letter Cites cGMP Violations

Drug Industry Daily
KEYWORDS FDA
A A

The FDA issued a warning letter to Indian drugmaker Wockhardt, citing violations of current good manufacturing practices (cGMPs) at its facility in Aurangabad, India.

To View This Article:

Login

Subscribe To Drug Industry Daily